Open Access
Issue
Med Sci (Paris)
Volume 37, Number 5, Mai 2021
La révolution médicale du dépistage néonatal – Une aventure médicale scientifique et sociétale
Page(s) 544 - 546
Section Le Magazine
DOI https://doi.org/10.1051/medsci/2021048
Published online 18 May 2021
  1. De Thé H, Pandolfi PP, Chen Z. Acute promyelocytic leukemia: a paradigm for oncoprotein-targeted cure. Cancer Cell 2017 ; 32 : 552–560. [Google Scholar]
  2. Burnett AK, Russel NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol 2015 ; 16 : 1295–1305. [Google Scholar]
  3. Kayser S, Rahmé R, Martinez-Cuadron D, et al. Outcome of older (≥ 70 years) APL patients frontline treated with or without arsenic trioxide: an international collaborative study. Leukemia 2020; 34 : 2333–41. [Google Scholar]
  4. Lo-Coco F, Di Donato L, Schlenk RF. Targeted therapy alone for acute promyelocytic leukemia. N Engl J Med 2016 ; 374 : 1197–1198. [Google Scholar]
  5. Lo-Coco F, Orlando SM, Platzbecker U. Treatment of acute promyelocytic leukemia. N Engl J Med 2013 ; 369 : 1472. [Google Scholar]
  6. Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood 2019 ; 133 : 1630–1643. [Google Scholar]
  7. Beitinjaneh A, Jang S, Roukoz H, et al. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. Leuk Res 2010 ; 34 : 831–836. [Google Scholar]
  8. Breccia M, Loglisci G, Loglisci MG, et al. FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis. Haematologica 2013 ; 98 : e161–e163. [Google Scholar]
  9. Lucena-Araujo AR, Kim HT, Jacoma RH, et al. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International consortium on acute promyelocytic leukemia study. Ann Hematol 2014 ; 93 : 2001–2010. [Google Scholar]
  10. Kelly LM, Kutok JL, Williams IR, et al. PML/RARa and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA 2002 ; 99 : 8283–8288. [Google Scholar]
  11. Ablain J, Rice K, Soilihi H, et al. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure. Nat Med 2014 ; 20 : 167–174. [Google Scholar]
  12. Cicconi L, Divona M, Ciardi C, et al. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. Leukemia 2016 ; 30 : 1987–1992. [Google Scholar]
  13. Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 2012 ; 120 : 1570–1580. [Google Scholar]
  14. Iland HJ, Collins M, Bradstock K, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol 2015 ; 2 : e357–e366. [Google Scholar]
  15. Iaccarino L, Ottone T, Divona M, et al. Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia. Br J Haematol 2016 ; 172 : 909–913. [Google Scholar]
  16. Lehmann-Che J, Bally C, Letouzé E, et al. Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia. Nat Commun 2018 ; 9 : 2047. [Google Scholar]
  17. Madan V, Shyamsunder P, Han L, et al. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia 2016 ; 30 : 1672–1681. [Google Scholar]
  18. Esnault C, Rahmé R, Rice KL, et al. FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias. Blood 2019 ; 133 : 1495–1506. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.